πŸ‡ΊπŸ‡Έ FDA
Patent

US 10392376

Heterocyclic inhibitors of ATR kinase

granted A61KA61K2300/00A61K45/06

Quick answer

US patent 10392376 (Heterocyclic inhibitors of ATR kinase) held by The Board of Regents of the University of Texas System expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
32
CPC classes
A61K, A61K2300/00, A61K45/06, A61P, A61P35/00